Dr Hebaallah Hashiesh
About me
Hardworking, self-motivated scientist and experienced lecturer with a Ph.D. in Biomedical Science with over ten years of experience in academia. My research interests are to explore novel therapeutic targets for the treatment of various human pathologies, including diabetic complications, neurodegenerative disorders, and chronic diseases, with a focus on drug discovery and translational research. Self-directed and motivated professional with a highly ethical, meticulous, and thorough approach.
Dr. Hebaallah Mamdouh Hashiesh is a biomedical scientist and pharmacologist with over ten years of experience in academic research and teaching. She is currently a Postdoctoral Fellow at Khalifa University, Abu Dhabi, where her research focuses on identifying novel molecular targets for chronic and neuroinflammatory diseases, with particular emphasis on multiple sclerosis, diabetes-related complications, and translational drug discovery.
Dr. Hashiesh earned her PhD in Biomedical Science from the United Arab Emirates University, graduating with a perfect GPA. Her doctoral work provided pioneering evidence for the therapeutic potential of cannabinoid type 2 (CB2) receptor activation in diabetic cardiomyopathy, demonstrating its role in reducing oxidative stress, inflammation, fibrosis, and inflammasome activation without psychotropic side effects. She also holds an MSc and BSc in Pharmaceutical Sciences from Helwan University, Egypt, where she graduated with Excellent Honours.
Her research expertise spans in vivo disease models, cell culture, molecular and biochemical techniques, and advanced histological and imaging methods. Dr. Hashiesh has published extensively in high-impact international journals and has presented her work at major international scientific conferences. She also serves as a peer reviewer for several reputable scientific journals.
In addition to her research career, Dr. Hashiesh has substantial teaching experience as a former Lecturer in Pharmacology and Toxicology, with a strong commitment to mentoring early-career researchers and graduate students. Her work is driven by a passion for rigorous, ethical science aimed at advancing therapeutic strategies for complex human diseases.
Other Memberships/Affiliations
Degrees:
2. Hebaallah Mamdouh Hashiesh, Sheikh Azimullah, M.F. Nagoor Meeran, Dhanya Saraswathiamm, Seenipandi Arunachalam, Niraj Kumar Jha, Bassem Sadek, Ernest Adeghate, Gautam Sethi, Alia Albawardi, Saeeda Al Marzooqi and Shreesh Ojha. Cannabinoid 2 receptor activation protects against diabetic cardiomyopathy through inhibition of AGE/RAGE-induced oxidative stress, fibrosis, and inflammasome activation. Journal of Pharmacology and Experimental Therapeutics 2024, DOI: https://doi.org/10.1124/jpet.123.002037.
3. Hebaallah Mamdouh Hashiesh, Azimullah Sheikh, Mohamed Fizur Nagoor Meeran, Dhanya Saraswathiamma, Niraj Kumar Jha, Bassem Sadek, Ernest Adeghate, Saeed Tariq, Saeeda Al Marzooqi, Shreesh Ojha. "Β-caryophyllene, a dietary phytocannabinoid, alleviates diabetic cardiomyopathy in mice by inhibiting oxidative stress and inflammation activating cannabinoid type-2 receptors. ACS Pharmacology & Translational Science 2023, 10.1021/acsptsci.3c00027. tps://doi.org/10.1021/acsptsci.3c00027.
4. Hebaallah Mamdouh Hashiesh, Niraj Kumar Jha, Shilu Deepa Thomas, Bassem Sadek, Sanjay Kumar, Ernest Adeghate, Shreesh Ojha., Chapter 15 - Targeting the CB (2) receptor to delay progression of cardiovascular diseases. In Medicinal Usage of Cannabis and Cannabinoids, Preedy, V. R.; Patel, V. B.; Martin, C. R., Eds. Academic Press: 2023; pp 171-182.
5. Hebaallah Mamdouh Hashiesh, Charu Sharma, Sameer N Goyal, Bassem Sadek, Niraj Kumar Jha, Juma Al Kaabi, Shreesh Ojha. A focused review on CB2 receptor-selective pharmacological properties and therapeutic potential of β-caryophyllene, a dietary cannabinoid. Biomedicine & Pharmacotherapy 2021, 140, 111639, doi:https://doi.org/10.1016/j.biopha.2021.111639.
6. Hebaallah Mamdouh Hashiesh, Niraj Kumar Jha, Charu Sharma, Piyush Kumar Gupta, Saurabh Kumar Jha, Chandragouda R Patil, Sameer N Goyal, Shreesh K Ojha. Pharmacological potential of JWH133, a cannabinoid type 2 receptor agonist in neurodegenerative, neurodevelopmental and neuropsychiatric diseases. European Journal of Pharmacology 2021, 909, 174398, doi:https://doi.org/10.1016/j.ejphar.2021.174398.
7. Hebaallah Mamdouh Hashiesh, Charu Sharma, Sameer N Goyal, Niraj Kumar Jha, Shreesh Ojha. Pharmacological Properties, Therapeutic Potential and Molecular Mechanisms of JWH133, a CB2 Receptor-Selective Agonist. Frontiers in Pharmacology 2021, 12, 702675-702675, doi:10.3389/fphar.2021.702675.
8. Niraj Kumar Jha, Charu Sharma, Hebaallah Mamdouh Hashiesh, Seenipandi Arunachalam, MF Meeran, Hayate Javed, Chandragouda R Patil, Sameer N Goyal, Shreesh Ojha. β-Caryophyllene, A Natural Dietary CB2 Receptor Selective Cannabinoid can be a Candidate to Target the Trinity of Infection, Immunity, and Inflammation in COVID-19. Frontiers in Pharmacology 2021, 12, 590201, doi:10.3389/fphar.2021.590201.
9. MF Nagoor Meeran, Sheikh Azimullah, Hebaallah Hashiesh Mamoudh, Charu Sharma, Sanjay Kumar, Sameer N Goyal, Shreesh Ojha. Nerolidol, a Sesquiterpene from the Essential Oils of Aromatic Plants, Attenuates Doxorubicin-Induced Chronic Cardiotoxicity in Rats. Journal of Agricultural and Food Chemistry 2021, 69, 7334-7343, doi:10.1021/acs.jafc.0c05667.
10. MF Nagoor Meeran, A Seenipandi, Hayate Javed, Charu Sharma, Hebaallah Mamdouh Hashiesh, Sameer N Goyal, Niraj Kumar Jha, Shreesh Ojha. Can limonene be a possible candidate for evaluation as an agent or adjuvant against infection, immunity, and inflammation in COVID-19? Heliyon 2021, 7, e05703, doi:https://doi.org/10.1016/j.heliyon.2020.e05703.
11. Hebaallah Mamdouh Hashiesh, MF Nagoor Meeran, Charu Sharma, Bassem Sadek, Juma Al Kaabi, Shreesh K Ojha. Therapeutic Potential of β-Caryophyllene: A Dietary Cannabinoid in Diabetes and Associated Complications. Nutrients 2020, 12, doi:10.3390/nu12102963.
12. Hebaallah M Hashiesh, Abeer A Elkhoely, Amany A Eissa, Mahmoud M Youns. Rosmarinic acid enhances cisplatin cytotoxicity in hepg2 cell line and attenuates its nephrotoxicity in mice, International Journal of Pharmaceutical Sciences and Research 9, 2731-2743, 2018.
13. Hebaallah Hashiesh. (2018). Combination of chemotherapeutic agents with antioxidants “Rosmarinic acid enhances Cisplatin cytotoxicity in HepG2 cell line and attenuates its nephrotoxicity in mice”. Riga, Latvia: LAP LAMBERT Academic Publishing. https://www.morebooks.de/shop-ui/shop/product/9786139876693